Abstracts tagged "Lupus nephritis"

Abstract Number: 0066 • ACR Convergence 2022
Identifying Childhood-Onset Systemic Lupus Erythematosus, Lupus Nephritis, and End-Stage Kidney Disease Definitions Within an Administrative Claims Database
Emily Smitherman¹, Rouba Chahine¹, Aimee Hersh² and Jeffrey Curtis³, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Utah, Salt Lake City, UT, ³University of Alabama at Birmingham, Hoover, AL
Background/Purpose: Data is lacking regarding modern real-world practices and disease outcomes of individuals with childhood-onset systemic lupus erythematosus (cSLE) and lupus nephritis, especially across multiple…
Abstract Number: 0358 • ACR Convergence 2022
Long-term Safety and Efficacy of Voclosporin in Hispanic and Latino Patients with Lupus Nephritis
Ellen M. Ginzler¹, Amit Saxena², Victoria Bal³, Vanessa Birardi⁴ and Henry Leher⁴, ¹SUNY Downstate Health Sciences University, Department of Medicine, Brooklyn, NY, ²NYU School of Medicine, New York, NY, ³Aurinia Pharmaceuticals, Inc., Victoria, BC, Canada, ⁴Aurinia Pharmaceuticals Inc, Rockville, MD
Background/Purpose: The AURORA 1 study demonstrated that addition of voclosporin to MMF and low-dose steroids significantly increased complete renal response rates at 52 weeks, with…
Abstract Number: 0651 • ACR Convergence 2022
Inflammatory Dendritic Cell Drive Intra-renal T Cells to Double-negative T Cell in Lupus Nephritis
Latha Prabha Ganesan, Shane Bruckner, Noushin Saljoughian, James Turman, Murugesan Rajaram, Brad Rovin, Wael Jarjour and Samir Parikh, The Ohio State University, Columbus, OH
Background/Purpose: The pathogenesis of lupus nephritis (LN) is incompletely understood stalling progress and resulting in suboptimal patient outcomes. We previously identified a novel inflammatory dendritic…
Abstract Number: 1376 • ACR Convergence 2022
Eculizumab Is Safe as an Adjunctive Therapy in Systemic Lupus Erythematosus with Severe Refractory Nephritis with or Without Thrombotic Microangiopathy in Children
Maria Pereira¹, Angela Chun¹, Leigh Stubbs¹ and Marietta De Guzman², ¹Baylor College of Medicine, Houston, TX, ²Baylor College of Medicine/ Texas Children's Hospital, Houston, TX
Background/Purpose: Eculizumab is a monoclonal antibody that prevents the cleavage of C5, which inhibits the formation of the terminal complement complex. It is approved in…
Abstract Number: 1718 • ACR Convergence 2022
Parenchymal INFγ Response Regulates Murine Lupus Nephritis
Minjung Kim¹, Anthony Marinov¹, Mark Shlomchik² and Jeremy Tilstra², ¹University of Pittsburgh, Pittsburgh, ²University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Lupus nephritis is the most common life-threatening end-organ complication of SLE. Interstitial infiltrates, specifically T cells, are major predictors of disease outcomes. We recently…
Abstract Number: 0068 • ACR Convergence 2022
Differential Diagnostic Coding Patterns and Associated Sociodemographic Factors in Childhood-Onset Lupus Nephritis
Emily Smitherman¹, Rouba Chahine¹, Aimee Hersh² and Jeffrey Curtis³, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Utah, Salt Lake City, UT, ³University of Alabama at Birmingham, Hoover, AL
Background/Purpose: Disparities in long-term kidney outcomes have been documented in patients with childhood-onset systemic lupus erythematosus (cSLE) complicated by lupus nephritis (LN). However, there remains…
Abstract Number: 0514 • ACR Convergence 2022
Renal Response Outcomes of North American Youth with Proliferative Lupus Nephritis Treated with the EuroLupus versus NIH Cyclophosphamide Dosing Regimen
Christine Wang¹, Rebecca Sadun², Wenru Zhou³, Kristen Miller³, Claire Palmer³, Stacy P Ardoin⁴, Christine Bacha⁵, Emily Hause⁶, Joyce Hui-Yuen⁷, Nicole Ling⁸, Maria Pereira⁹, Meredith Riebschleger¹⁰, Kelly Rouster-Stevens¹¹, Aliese Sarkissian¹², Julia Shalen¹³, William Soulsby¹⁴, Marinka Twilt¹⁵, Eveline Wu¹⁶, Laura Lewandowski¹⁷, Scott Wenderfer¹⁸ and Jennifer Cooper¹⁹, ¹Children's Hospital of Colorado/University of Colorado, Denver, CO, ²Duke University, Durham, NC, ³University of Colorado School of Medicine, Aurora, CO, ⁴Division of Rheumatology, Nationwide Children's Hospital and Department of Pediatrics, The Ohio State University, Columbus, OH, ⁵Nationwide Children's Hospital, Columbus, OH, ⁶University of Minnesota, Minneapolis, MN, ⁷Cohen Children’s Medical Center, Hofstra-Northwell School of Medicine, Feinstein Institutes for Medical Research, Queens, NY, ⁸UCSF, San Francisco, CA, ⁹Baylor College of Medicine, Houston, TX, ¹⁰University of Michigan, Ann Arbor, MI, ¹¹Division of Pediatric Rheumatology, Department of Pediatrics, Emory University School of Medicine; Children’s Healthcare of Atlanta, Atlanta, GA, ¹²University of North Carolina at Chapel Hill, Chapel Hill, NC, ¹³Johns Hopkins University, Baltimore, MD, ¹⁴University of California, San Francisco, San Francisco, CA, ¹⁵Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ¹⁶University of North Carolina, Chapel Hill, NC, ¹⁷NIAMS, NIH, Bethesda, MD, ¹⁸British Columbia Children's Hospital, Vancouver, BC, Canada, ¹⁹Children's Hospital of Colorado/University of Colorado, Aurora, CO
Background/Purpose: There have been no published studies comparing renal outcomes of youth with proliferative lupus nephritis (LN) treated with the lower-dose EuroLupus (EL) cyclophosphamide (CYC)…
Abstract Number: 0655 • ACR Convergence 2022
Proteomic Analysis of Histological Lesions Lupus Nephritis Identifies an Inflammatory Signature of Fibrous Crescents
Alessandra Ida Celia¹, Jeffery Hodgin², Avi Rosenberg³, Laurence S Magder⁴, Jill Buyon⁵, Betty Diamond⁶, Judith James⁷, William Apruzzese⁸, Paride Fenaroli⁹, Derek Fine¹, Jose Monroy-Trujillo¹, Mohamed G. Atta¹, Peter izmirly¹⁰, Michael Belmont⁵, Anne Davidson⁶, Daniel W. Goldman¹¹, the Accelerating Medicines Partnership (AMP) RA/SLE¹², Michelle Petri¹¹ and Andrea Fava¹, ¹Johns Hopkins University, Baltimore, MD, ²University of Michigan, Ann Arbor, MI, ³Johns Hopkins University, Ballwin, MO, ⁴University of Maryland, Department of Epidemiology and Public Health, Baltimore, MD, ⁵NYU Grossman School of Medicine, New York, NY, ⁶Feinstein Institutes for Medical Research, Manhasset, NY, ⁷Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁸Brigham and Women's Hospital, Boston, MA, ⁹Università degli Studi di Parma, Parma, Emilia-Romagna, Italy, ¹⁰NYU Long Island School of Medicine, New York, NY, ¹¹Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD, ¹²Multiple Insitutions
Background/Purpose: We employed urine proteomics to define the molecular signatures associated with the histological features quantified by the NIH activity and chronicity indices. Methods: Glomerular…
Abstract Number: 1440 • ACR Convergence 2022
Interrelation of T-cell Cytokines and Autoantibodies in Lupus Nephritis: A Cross-sectional Study
Fatima Alduraibi¹, Kathryn Sullivan¹, Winn Walter Chatham², Hui-Chen Hsu¹ and John Mountz¹, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Clinical Immunology and Rheumatology, Birmingham, AL
Background/Purpose: To determine if different classes of lupus nephritis (LN) are correlated with specific circulating autoantibodies (autoAbs) and T-helper cell cytokines and other manifestations of…
Abstract Number: 1719 • ACR Convergence 2022
NLRP12 Deficiency Mice Present Severer Lupus Nephritis in a Pristane-Induced Lupus Like Model
Yen Po Tsao¹, Fang-Yu Tseng², Ming-Han Chen³ and SZUTING CHEN², ¹Taipei Veterans General Hospital, Taipei, Taiwan, ²National Yang Ming Chao Tung University, Taipei, Taiwan, ³Division of Allergy, Immunology & Rheumatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, Taipei, Taiwan
Background/Purpose: Systemic lupus erythematous (SLE) is a systemic autoimmune disease that interferon (IFN) signature involved in the progress. NLRP12 (NOD-like receptor family (NLR) pyrin domain…
Abstract Number: 0099 • ACR Convergence 2022
Impact of Multimodal Independent Medical Education on Improving Outcomes and Reducing Disparities in Systemic Lupus Erythematosus and Lupus Nephritis
Lisa Handley¹, Kimberly Lovin Nealy² and Sarah A. Nisly³, ¹Clinical Care Options, Clive, IA, ²Clinical Care Options, Matthews, NC, ³Clinical Care Options, Reston, VA
Background/Purpose: Due to its range of manifestations and lack of specific findings, early diagnosis of SLE is often a challenge, and serious complications, including LN,…
Abstract Number: 0536 • ACR Convergence 2022
Change in Urinary Biomarkers at Three Months Predicts 1-year Treatment Response of Lupus Nephritis Better Than Proteinuria
Andrea Fava¹, Laurence S Magder², Daniel W. Goldman³, Jill Buyon⁴, Betty Diamond⁵, Joel Guthridge⁶, William Apruzzese⁷, Derek Fine¹, Jose Monroy-Trujillo¹, Mohamed G. Atta¹, Peter Izmirly⁴, H Michael Belmont⁸, Anne Davidson⁵, Maria Dall'Era⁹, Deepak Rao⁷, Arnon Arazi¹⁰, Nir Hacohen¹¹, Soumya Raychaudhuri⁷, the Accelerating Medicines Partnership (AMP) RA/SLE¹² and Michelle Petri³, ¹Johns Hopkins University, Baltimore, MD, ²University of Maryland, Department of Epidemiology and Public Health, Baltimore, MD, ³Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD, ⁴NYU Grossman School of Medicine, New York, NY, ⁵Feinstein Institutes for Medical Research, Manhasset, NY, ⁶Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁷Brigham and Women's Hospital, Boston, MA, ⁸NYU School of Medicine, New York, NY, ⁹University of California, San Francisco, San Francisco, ¹⁰Feinstein Institutes for Medical Research, Melrose, MA, ¹¹Broad Institute, Cambridge, MA, ¹²Multiple Insitutions
Background/Purpose: A decline of urine protein-to-creatinine ratio (UPCR) to < 0.5 is associated with better long-term preservation of kidney function in lupus nephritis (LN). UPCR…
Abstract Number: 0746 • ACR Convergence 2022
Telemedicine for Follow-up of Lupus Nephritis in the Covid-19 Outbreak: A Pragmatic Randomized Controlled Trial
Ho SO¹, Evelyn Chow², Isaac Cheng¹, Xerox Lau², Tena Li¹, Cheuk Chun Szeto² and Lai-shan Tam¹, ¹The Chinese University of Hong Kong, Hong Kong, China, ²The Chinese University of Hong Kong, Hong Kong, Hong Kong
Background/Purpose: During the pandemic, vulnerable patients such as those with lupus nephritis (LN) faced the difficult choice between COVID-19 infection risk during a clinic visit…
Abstract Number: 1450 • ACR Convergence 2022
Impact of Time to Remission, Flares and Time on Immunosuppressives on the Estimated Glomerular Filtration Rate in Lupus Nephritis
KONSTANTINOS TSELIOS¹, Dafna Gladman², Jiandong Su³ and Murray Urowitz⁴, ¹McMaster University, Population Health Research Institute, Hamilton, ON, Canada, ²Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, ON, Canada, ³Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and University of Toronto, Toronto, ON, Canada, ⁴University of Toronto, University Health Network, Schroeder Arthritis Institute, Toronto, ON, Canada
Background/Purpose: Time to complete remission, subsequent flares and time on immunosuppressives after complete remission are major determinants of the progression to advanced chronic kidney disease…
Abstract Number: 1722 • ACR Convergence 2022
The ERβ Agonist, WT-IV-012, Suppresses the Inflammatory Response in Systemic Lupus Erythematosus
Shane Bruckner¹, Braden Zeno¹, William Willis², Chad Bennett¹ and Wael Jarjour¹, ¹The Ohio State University, Columbus, OH, ²Ohio State, Reynoldsburg, OH
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by multiple organ damage, mainly affecting young women between the ages of 15 and 45…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].